FIELD: medicine.
SUBSTANCE: disclosed is a method of treating central nervous system diseases selected from Alzheimer disease and amyotrophic lateral sclerosis, comprising administering to a patient in need thereof a pharmaceutical composition containing an anti-OX40 antibody or an anti-OX40L antibody. Disclosed is the use of an anti-OX40 antibody or anti-OX40L antibody for producing a pharmaceutical composition for treating central nervous system diseases, selected from Alzheimer's disease and amyotrophic lateral sclerosis, wherein the treatment involves administering to a patient in need thereof a pharmaceutical composition containing an anti-OX40 antibody or an anti-OX40L antibody.
EFFECT: proposed group of inventions provides effective treatment of Alzheimer's disease and amyotrophic lateral sclerosis.
14 cl, 15 dwg, 2 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| REDUCED SYSTEMIC LEVELS OR ACTIVITY OF REGULATORY T-CELLS FOR TREATING DISEASE AND CENTRAL NERVOUS SYSTEM INVOLVEMENT | 2017 |
|
RU2815892C1 |
| REDUCED LEVELS OR ACTIVITY OF SYSTEMIC REGULATORY T CELLS FOR TREATING DISEASE OR CNS INJURY | 2015 |
|
RU2690670C2 |
| PHARMACEUTICAL COMPOSITION FOR TREATING MALIGNANT NEOPLASM | 2018 |
|
RU2730984C1 |
| METHOD OF TREATING ALZHEIMER'S DISEASE THROUGH REGULATION OF INTESTINAL MICROORGANISMS | 2020 |
|
RU2810079C2 |
| METHOD FOR TREATMENT OF ALZHEIMER'S DISEASE BY T-CELL INHIBITION OF AMINO ACID UPTAKE | 2020 |
|
RU2791665C1 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
| METHOD OF IDENTIFYING PATIENT SENSITIVE TO MEDICINAL PRODUCT BASED ON MANNURONIC ACID OLIGOSACCHARIDES AMONG PATIENTS WITH ALZHEIMER'S DISEASE | 2020 |
|
RU2806017C2 |
| METHOD OF TREATMENT OF ALZHEIMER'S DISEASE THROUGH REGULATION OF AMINO ACID LEVEL | 2020 |
|
RU2801150C1 |
| COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DISTURBANCES | 2005 |
|
RU2387453C2 |
| PEPTIDE TOLEROGENIC COMPOUND | 2021 |
|
RU2766340C1 |
